Login to Your Account

Drug developers flock to EMA's Prime scheme

By Cormac Sheridan
Staff Writer

Thursday, April 7, 2016

HAMBURG – By late Wednesday afternoon, 18 drug developers filed applications for inclusion in the first batch of projects to benefit from a suite of regulatory supports under the EMA's priority medicines initiative, Prime, which aims to accelerate the development and approval of medicines with the potential to make significant clinical impact in areas of unmet medical need.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription